Faricimab
drugOn this page
Also known as Faricimab svoaFaricimab-svoaRg-7716RG7716RG77161RO-6867461Ro6867461VabysmoY8ha1i28d3
Summary
Faricimab (CHEMBL4297750) is an approved antibody (ATC S01LA09); indicated across 9 conditions including wet macular degeneration and ocular vascular disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: S01LA09
- Indications: 9 conditions
- Clinical trials: 39
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297750 |
| Name | Faricimab |
| Type | Antibody |
| Max phase | 4 |
| ATC | S01LA09 |
Also known as: Faricimab, Faricimab svoa, Faricimab-svoa, Rg-7716, RG7716, RG77161, RO-6867461, Ro6867461, RO6867461, Vabysmo, Y8ha1i28d3, FARICIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| wet macular degeneration | 4 | MONDO:0005417 | EFO:0004683 |
| ocular vascular disorder | 4 | MONDO:0005552 | EFO:0005753 |
| age-related macular degeneration | 3 | MONDO:0005150 | EFO:0001365 |
| macular degeneration | 3 | MONDO:0003004 | EFO:0009606 |
| choroidal neovascularization | 2 | MONDO:0810000 | MONDO:0810000 |
| eye disorder | 1 | MONDO:0005328 | HP:0000478 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 39.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 11 |
| Not specified | 10 |
| PHASE2 | 7 |
| PHASE4 | 6 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05224102 | PHASE4 | ACTIVE_NOT_RECRUITING | A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema |
| NCT05610319 | PHASE4 | ACTIVE_NOT_RECRUITING | Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
| NCT06191094 | PHASE4 | ENROLLING_BY_INVITATION | Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy |
| NCT06795048 | PHASE4 | ACTIVE_NOT_RECRUITING | A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration |
| NCT06875245 | PHASE4 | RECRUITING | Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals |
| NCT05941715 | PHASE4 | COMPLETED | Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration |
| NCT05844982 | PHASE3 | RECRUITING | Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy |
| NCT06176352 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia |
| NCT06790784 | PHASE3 | RECRUITING | Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR |
| NCT03622580 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) |
| NCT03622593 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema |
| NCT03823287 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) |
| NCT03823300 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) |
| NCT04432831 | PHASE3 | COMPLETED | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema |
| NCT04740905 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion |
| NCT04740931 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion |
| NCT04777201 | PHASE3 | COMPLETED | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration |
| NCT06572553 | PHASE2/PHASE3 | UNKNOWN | Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients |
| NCT06850922 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema |
| NCT06908876 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME） |
| NCT02484690 | PHASE2 | COMPLETED | A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
| NCT02699450 | PHASE2 | COMPLETED | A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema |
| NCT03038880 | PHASE2 | COMPLETED | Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration |
| NCT04597918 | PHASE2 | COMPLETED | A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab |
| NCT05681884 | PHASE2 | COMPLETED | Safety and Efficacy of Faricimab in Patients With NPDR |
| NCT07093385 | PHASE2 | COMPLETED | Intravitreal Faricimab in Patients With Refractory Macular Edema |
| NCT07425522 | PHASE1 | RECRUITING | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) |
| NCT01941082 | PHASE1 | COMPLETED | A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration |
| NCT07484074 | PHASE1 | COMPLETED | A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 |
| NCT05476926 | Not specified | ACTIVE_NOT_RECRUITING | A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products |
| NCT06271330 | Not specified | RECRUITING | Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. |
| NCT06439576 | Not specified | ACTIVE_NOT_RECRUITING | Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) |
| NCT06680817 | Not specified | RECRUITING | A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) |
| NCT07088445 | Not specified | NOT_YET_RECRUITING | Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration |
| NCT07249216 | Not specified | RECRUITING | Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting |
| NCT07520045 | Not specified | RECRUITING | Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab |
| NCT06124677 | Not specified | COMPLETED | Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments |
| NCT06231121 | Not specified | COMPLETED | Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab |
| NCT07144865 | Not specified | COMPLETED | Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).